Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (2811)	12/9/2019 1:12:40 PM
From: Miljenko Zuanic	Respond to of 3557

Maybe. But, there is promise in THOR unnatural AA technology...IF one knows how to use it. I am glad that sanofi payed for THOR, and REGN may benefit from it. IL-2 mimetic + PD-1 as IO-IO may not be that bad, and actually competitive. Also, IL-2 mimetic may burst PD1-chemo results, without adding toxicity and minimal riise in expense relative to added benefit. Normally, all this is in air...does not hurt to dream bit, here and there. :-)